Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

Open access

Abstract

Rationale Some of the behavioral consequences of deficits in N-methyl-D-aspartate (NMDA) glutamate receptor function are thought to arise from the disinhibition of cortical glutamatergic circuitry.Objective This study evaluated whether pretreatment with a drug that reduces glutamatergic activation, the group II metabotropic glutamate receptor (mGluR) agonist, LY354740, reduced the cognitive effects of the NMDA glutamate receptor antagonist, ketamine, in healthy human subjects.Methods Nineteen healthy human subjects completed 3 test days during which LY354740 (matched placebo, 100 mg, 400 mg) was administered under double-blind conditions 4 h prior to the single-blind intravenous administration of saline and 5.7 h prior to ketamine administration (bolus of 0.26 mg/kg over 1 min, infusion of 0.65 mg/kg per hour for 100 min). Thus on each test day each subject received a single dose of LY354740 (or its matched placebo) and both saline and ketamine infusions.Results Ketamine impaired attention, working memory, and delayed recall. It also produced positive and negative symptoms, perceptual changes, and dysphoric mood. LY354740 did not have a significant effect on working memory on the placebo day; however, it produced a significant dose-related improvement in working memory during ketamine infusion.Conclusions These data provide preliminary and suggestive evidence that LY354740 or other group II mGluR agonists might play a role in treating working memory impairment related to deficits in NMDA receptor function.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00213-004-1982-8

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 4

  1. Farber NB, Newcomer JW, Olney JW (1999) Lamotrigine prevents NMDA antagonist neurotoxicity. Schizophr Res 36:308
  2. Gordon M (1983) Gordon diagnostic systems. Gordon Systems, DeWitt
  3. Krystal JH, Belger A, Kirino E, Gore J, McCarthy G (1998a) Ketamine effects on the cortical processing of novelty in humans assessed with fMRI. Soc Neurosci Abstr 24:#104.7
  4. Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured clinical interview for DSM-III-R-non-patient edition (SCID-NP, version 1.0 with supplement for DSM-IV). American Psychiatric Press, Washington D.C.

Cited by

See all 273

Metadata

Authors
Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., & Breier, A.
Affiliations
  • VA Connecticut Healthcare System (US)
  • Yale University (US)
  • Eli Lilly (United States) (US)
Corresponding author
Krystal, John H.
Venue
Psychopharmacology
Published
2004-08-10
Volume
179
Issue
1
Pages
303-309
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W2072471087
Cited by
272
References
42
Citations by year
2026: 6 · 2025: 3 · 2024: 4 · 2023: 12 · 2022: 7 · 2021: 7 · 2020: 5 · 2019: 8 · 2018: 8 · 2017: 9 · 2016: 11 · 2015: 16 · 2014: 8 · 2013: 18 · 2012: 17
FWCI
5.63
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • National Institutes of Health (5k05aa014906-03)
  • National Institute on Alcohol Abuse and Alcoholism (KO5 AA014906-01)
  • National Institute of Mental Health (5P50 MH44866-12, P50MH044866)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
ketamine, LY354740, NMDA receptor antagonism, working memory, cognitive impairment, attention, delayed recall, positive and negative symptoms
MeSH terms
Adult, Bridged Bicyclo Compounds, Double-Blind Method, Female, Humans, Ketamine, Male, Memory, Single-Blind Method, Receptors, N-Methyl-D-Aspartate, Receptors, Metabotropic Glutamate, Excitatory Amino Acid Agonists, Excitatory Amino Acid Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. https://app.cochat.ai/papers/10.1007/s00213-004-1982-8
The paper
Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., & Breier, A. (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology. https://doi.org/10.1007/s00213-004-1982-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.